American Clinical Research Services, now known as Elixia, has rebranded to reflect its expanded clinical research and patient recruitment capabilities. This change represents the company’s mission to accelerate drug development and improve patient outcomes.
Elixia combines the expertise of premier clinical research sites with a patient recruitment engine. This allows it to conduct clinical trials with efficiency and precision. Through strategic acquisitions, Elixia has strengthened its services and positioned itself as a key industry player.
With facilities in multiple states, Elixia studies various conditions, including metabolic health, nephrology, neuroscience, and infectious diseases. Its technological advancements enhance patient recruitment and provide sponsors with critical insights.
Elixia remains committed to its partners, patients, and stakeholders as it enters this new phase. The company’s commitment to drug development and healthcare delivery is evident in its expanded capabilities and integrated approach. With its robust network and expertise, Elixia is poised to significantly impact the healthcare landscape by driving innovations that bring new treatments to patients faster and more effectively.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
